Court Grants Natera's Request to Include Additional Patent in its Lawsuit Against NeoGenomics [Yahoo! Finance]
NeoGenomics, Inc. (NASDAQ: NEO) had its price target raised by analysts at Bank of America Co. from $18.00 to $19.00. They now have a "neutral" rating on the stock.
NeoGenomics' Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma [Yahoo! Finance]
NeoGenomics’ Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
NeoGenomics, Inc. (NASDAQ: NEO) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $22.00 price target on the stock.